Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as $96.78 and last traded at $95.35, with a volume of 5603827 shares. The stock had previously closed at $91.57.

Analysts Set New Price Targets

DNTH has been the subject of several research reports. Wedbush upped their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Wells Fargo & Company started coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target for the company. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research note on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Stock Up 4.1%

The company has a market cap of $5.21 billion, a PE ratio of -23.09 and a beta of 1.18. The firm’s 50-day moving average is $86.46 and its 200-day moving average is $67.83.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 179,121 shares of company stock worth $15,059,454 in the last three months. 3.02% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after acquiring an additional 6,323 shares during the period. Invesco Ltd. increased its holdings in Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after acquiring an additional 4,962 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after acquiring an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at $27,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.